Published in Crit Care Med on August 01, 2010
Ischemia and reperfusion--from mechanism to translation. Nat Med (2011) 6.64
Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol (2012) 1.86
Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A (2012) 1.80
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest (2013) 1.58
Endothelial and Microcirculatory Function and Dysfunction in Sepsis. Clin Chest Med (2016) 1.42
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol (2011) 1.36
Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front Immunol (2013) 1.27
Lipopolysaccharide clearance, bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis. J Immunol (2013) 1.23
Animal models of sepsis. Virulence (2013) 1.22
Characterization of sparstolonin B, a Chinese herb-derived compound, as a selective Toll-like receptor antagonist with potent anti-inflammatory properties. J Biol Chem (2011) 1.14
In vivo platelet activation in critically ill patients with primary 2009 influenza A(H1N1). Chest (2012) 0.98
Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation (2014) 0.93
Targeting Toll-like receptors with small molecule agents. Chem Soc Rev (2013) 0.93
Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain. FASEB J (2013) 0.92
TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipid-induced inflammation and insulin resistance in muscle cells. Biosci Rep (2012) 0.89
Toll-like receptors and chronic inflammation in rheumatic diseases: new developments. Nat Rev Rheumatol (2016) 0.89
TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab (2015) 0.88
Sepsis and septic shock. Nat Rev Dis Prim (2016) 0.85
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol (2014) 0.84
MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol (2015) 0.83
Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics. J Med Chem (2011) 0.83
An endogenous factor mediates shock-induced injury. Nat Med (2013) 0.82
Selection, synthesis, and anti-inflammatory evaluation of the arylidene malonate derivatives as TLR4 signaling inhibitors. Bioorg Med Chem (2012) 0.80
How the Innate Immune System Senses Trouble and Causes Trouble. Clin J Am Soc Nephrol (2014) 0.80
Inflammatory targets of therapy in sickle cell disease. Transl Res (2015) 0.80
Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths. Crit Care Med (2010) 0.79
Renal effects of treatment with a TLR4 inhibitor in conscious septic sheep. Crit Care (2014) 0.79
Analgesic effect of TAK-242 on neuropathic pain in rats. Int J Clin Exp Med (2015) 0.78
Cardioprotection: a review of current practice in global ischemia and future translational perspective. Biomed Res Int (2014) 0.78
Caspases come together over LPS. Trends Immunol (2015) 0.78
Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation. ChemMedChem (2015) 0.77
Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide. EMBO Mol Med (2015) 0.77
Neuroprotective Effects of Resatorvid Against Traumatic Brain Injury in Rat: Involvement of Neuronal Autophagy and TLR4 Signaling Pathway. Cell Mol Neurobiol (2016) 0.77
The immune response: targets for the treatment of severe sepsis. Int J Inflam (2012) 0.77
E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat protein. Virol J (2014) 0.77
Current knowledge and future directions of TLR and NOD signaling in sepsis. Mil Med Res (2015) 0.77
Histidine-Rich Glycoprotein Prevents Septic Lethality through Regulation of Immunothrombosis and Inflammation. EBioMedicine (2016) 0.76
Snake Venom Disintegrin Inhibits the Activation of Toll-Like Receptors and Alleviates Sepsis through Integrin alphaVbeta3 Blockade. Sci Rep (2016) 0.76
Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state. Brain Behav Immun (2016) 0.75
Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets. J Leukoc Biol (2016) 0.75
Escherichia coli Braun Lipoprotein (BLP) exhibits endotoxemia - like pathology in Swiss albino mice. Sci Rep (2016) 0.75
The Fab Fragment of a Human Anti-Siglec-9 Monoclonal Antibody Suppresses LPS-Induced Inflammatory Responses in Human Macrophages. Front Immunol (2016) 0.75
A novel imidazopyridine derivative, X22, attenuates sepsis-induced lung and liver injury by inhibiting the inflammatory response in vitro and in vivo. Drug Des Devel Ther (2016) 0.75
Pharmacological TLR4 Inhibition Protects against Acute and Chronic Fat-Induced Insulin Resistance in Rats. PLoS One (2015) 0.75
Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF-κB and AP-1 Signaling in Keratinocytes and Mouse Skin. Photochem Photobiol (2016) 0.75
Genomics in cardiovascular diseases: analysis of the importance of the toll-like receptor signaling pathway. Int J Gen Med (2012) 0.75
Caffeic Acid Cyclohexylamide Rescues Lethal Inflammation in Septic Mice through Inhibition of IκB Kinase in Innate Immune Process. Sci Rep (2017) 0.75
Physiological aspects of Toll-like receptor 4 activation in sepsis-induced acute kidney injury. Acta Physiol (Oxf) (2016) 0.75
Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts through the Toll-like receptor 4-nuclear factor-κB signaling pathway and myoblast-derived tumor necrosis factor-α. PLoS One (2017) 0.75
The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. Front Physiol (2017) 0.75
TLR4 antagonist suppresses airway remodeling in asthma by inhibiting the T-helper 2 response. Exp Ther Med (2017) 0.75
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Comparison of two fluid-management strategies in acute lung injury. N Engl J Med (2006) 19.54
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med (2013) 17.37
A randomized trial of protocol-based care for early septic shock. N Engl J Med (2014) 16.05
Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA (2004) 11.27
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
Mortality after surgery in Europe: a 7 day cohort study. Lancet (2012) 9.96
Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review. JAMA (2002) 9.89
RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care (2006) 9.29
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med (2010) 8.58
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med (2006) 7.97
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med (2010) 6.69
Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA (2003) 6.24
Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet (2007) 6.07
National estimates of severe sepsis in United States emergency departments. Crit Care Med (2007) 5.99
Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med (2004) 5.90
Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med (2002) 5.84
Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA (2010) 5.80
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med (2005) 5.76
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med (2007) 5.65
Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology (2015) 5.52
Nighttime intensivist staffing and mortality among critically ill patients. N Engl J Med (2012) 5.22
Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA (2011) 5.08
Variation in critical care services across North America and Western Europe. Crit Care Med (2008) 5.00
Circulatory shock. N Engl J Med (2013) 4.95
Sepsis biomarkers: a review. Crit Care (2010) 4.76
Costs associated with delirium in mechanically ventilated patients. Crit Care Med (2004) 4.75
The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med (2002) 4.72
Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med (2010) 4.69
Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA (2012) 4.67
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med (2010) 4.64
An academia-industry partnership in health care. Lancet (2009) 4.61
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA (2003) 4.54
The effect of multidisciplinary care teams on intensive care unit mortality. Arch Intern Med (2010) 4.41
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med (2003) 4.04
Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology (2006) 4.03
Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med (2005) 3.97
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med (2002) 3.87
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (2005) 3.85
Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci (2010) 3.84
Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. Intensive Care Med (2005) 3.81
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med (2006) 3.53
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet (2012) 3.46
A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med (2005) 3.44
Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med (2008) 3.44
Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med (2014) 3.39
Severe sepsis in pre-hospital emergency care: analysis of incidence, care, and outcome. Am J Respir Crit Care Med (2012) 3.36
Biomedical research. The endangered lab chimp. Science (2007) 3.35
Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med (2011) 3.34
The epidemiology of mechanical ventilation use in the United States. Crit Care Med (2010) 3.28
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
Racial variation in the incidence, care, and outcomes of severe sepsis: analysis of population, patient, and hospital characteristics. Am J Respir Crit Care Med (2007) 3.17
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med (2014) 3.17
Intensive care unit quality improvement: a "how-to" guide for the interdisciplinary team. Crit Care Med (2006) 3.15
Pneumonia: still the old man's friend? Arch Intern Med (2003) 3.12
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Management of bleeding following major trauma: an updated European guideline. Crit Care (2010) 3.09
Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int (2002) 3.07
Microvascular response to red blood cell transfusion in patients with severe sepsis. Crit Care Med (2007) 3.06
Attitudes and perceptions of patients towards methods of establishing a DNA biobank. Cell Tissue Bank (2007) 3.05
Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med (2002) 3.02
Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int (2009) 2.97
C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest (2003) 2.95
Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Med (2009) 2.93
Organizational characteristics, outcomes, and resource use in 78 Brazilian intensive care units: the ORCHESTRA study. Intensive Care Med (2015) 2.92
Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest (2008) 2.90
Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA (2010) 2.87
Deviations from evidence-based clinical management guidelines increase mortality in critically injured trauma patients*. Crit Care Med (2012) 2.86
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med (2010) 2.86
The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med (2006) 2.84
Let us use the pulmonary artery catheter correctly and only when we need it. Crit Care Med (2005) 2.83
Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma (2010) 2.82